For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Gw Research Limited

USPTO Granted Patents = 49

EPO Patents = 25

Trademarks = 20

Forward Citations = 1,457

Loading Chart...

Loading Chart...

52 inventors (with patents filed for the assignee):

Geoffrey W Guy (32 out of 73 patents)

Stephen Wright (27 out of 61 patents)

Orrin Devinsky (16 out of 28 patents)

4. Benjamin Whalley (9 out of 20 patents)

5. Colin Stott (8 out of 17 patents)

6. Marie Woolley-Roberts (7 out of 11 patents)

7. Volker Knappertz (6 out of 11 patents)

8. James Brodie (6 out of 7 patents)

9. Jitinder Wilkhu (4 out of 5 patents)

10. Royston Gray (4 out of 6 patents)

11. Livio Luongo (4 out of 5 patents)

12. Elizabeth Thiele (3 out of 3 patents)

13. Rohini Rajyalaxmi Rana (3 out of 3 patents)

14. Rafael Maldonado (3 out of 6 patents)

15. Daniela Parolaro (3 out of 5 patents)

Core Competencies:

Cannabidiol

Cannabinoids

Epilepsy

Autism Spectrum Disorder

Neurodegenerative Diseases

Pharmaceutical Formulation

Oral Formulations

7-OH-CBD

Tuberous Sclerosis

Microparticle Formulations

Cannabidivarin

Multiple Myeloma

49 patents: Sort by Forward Citations

1. 12708632 - USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN (2026-08-18),

2. 12150927 - Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders (2024-11-26),

3. 11963937 - Use of cannabinoids in the treatment of epilepsy (2024-04-23),

4. 11944600 - Use of cannabinoids in the treatment of a neurodegenerative disease or disorder (2024-04-02),

5. 11865102 - Cannabidiol preparations and its uses (2024-01-09),

6. 11806319 - Pharmaceutical composition comprising a cannabinoid (2023-11-07),

7. 11793770 - 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy (2023-10-24),

8. 11766411 - Use of cannabinoids in the treatment of epilepsy (2023-09-26),

9. 11752111 - Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia (2023-09-12),

10. 11701330 - Use of cannabinoids in the treatment of epilepsy (2023-07-18),

11. 11684598 - Use of cannabinoids in the treatment of epilepsy (2023-06-27),

12. 11679087 - Use of cannabinoids in the treatment of Angelman syndrome (2023-06-20),

13. 11633369 - Use of cannabinoids in the treatment of epilepsy (2023-04-25),

14. 11590087 - Cannabidiol-type cannabinoid compound (2023-02-28),

15. 11446258 - Use of cannabinoids in the treatment of epilepsy (2022-09-20),

Company Overview

GW Research Limited, based in Cambridge, UK, specializes in the development of cannabinoid-based pharmaceutical formulations. The company focuses on innovative treatments for various medical conditions, including neurodegenerative diseases, epilepsy, and autism spectrum disorder. With a strong emphasis on cannabinoids such as cannabidiol and cannabidivarin, GW Research is dedicated to advancing the understanding and therapeutic potential of these compounds in addressing complex health challenges.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

49 Patents

#21 in Cambridge

#363 in United Kingdom

#14,293 in the World

Cambridge, United Kingdom

Gw Research Limited

Forward Citations = 1,457

52 inventors:

Geoffrey W Guy (32 out of 73 patents)

Stephen Wright (27 out of 61 patents)

Orrin Devinsky (16 out of 28 patents)

4. Benjamin Whalley (9 out of 20 patents)

5. Colin Stott (8 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gw Research Limited. Retrieved from https://idiyas.com/company/gw-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…